Cardiovascular drugs effects on cartilage, synovium, and subchondral bone
Cardiovascular Drugs Market |
Any substance that affects the function of the heart and
blood arteries is referred to as a cardiovascular drug. The cardiovascular
system is one of the most commonly used systems in medicine. Hypertension (high
blood pressure), angina
pectoris (chest pain caused by insufficient blood flow through the coronary
arteries to the heart muscle), heart failure (inadequate output of the heart
muscle in comparison to the needs of the rest of the body), and arrhythmias are
all conditions in which such drugs may be beneficial.
Drugs have three primary effects on the heart's function.
They can impact the force with which the heart muscle contracts (inotropic
effects), the frequency with which the heart beats (chronotropic effects), or
the regularity with which the heart beats (regularity effects) (rhythmic
effects).
The purpose of this study is to address the potential
effects of currently used cardiovascular
drugs on cartilage, synovium, and subchondral bone, with an emphasis on
mechanisms of action on ion channels in joint cells, pain control, inflammatory
modulation, and probable repercussions for OA progression. Drugs used to treat
cardiovascular disease may have an indirect effect on the synovial joint,
influencing chondrocyte function, which can be beneficial or harmful. As a
result, it's critical to see if any cardiovascular drugs may be tweaked to
treat specific OA characteristics in people with cardiovascular disease. We
summarised current information on the two chronic diseases, cardiovascular and
OA, as well as their origins, causes, and interrelationships at the molecular
level, medication use, and pharmacological therapy in this review. We also
looked at the mechanisms of action of ion channel modifying cardiovascular
medications and how they can affect cartilage ECM turnover, subchondral bone
remodelling, and the progression of OA. Understanding the complicated action of
cardiovascular medicines may aid in the resolution of critical therapeutic
concerns, such as how to avoid their side effects and whether pharmacological
cardiovascular treatment is advantageous for patients with metabolic OA.
Comments
Post a Comment